First Author: F.Ulaş TURKEY
Co Author(s): T. Bayram E. Uyar U. Dogan
Back to previous
To evaluate short-term intraocular pressure (IOP) changes after intravitreal injection of aflibercept and ranibizumab using pneumotonometer.
Ophthalmology Deparment, Abant Izzet Baysal University, Faculty of Medicine Hospital.
64 eyes of 64 consecutive patients with age-related macular degenation or diabetic maculopathy who underwent intravitreal injection of 0.05ml ranibizumab or aflibercept were included in this study. Vitreous reflux volume of the patients were also recorded and patients were divided into 3 groups according to vitreous reflux. Group 1 included patients with no detectable reflux, Group 2 included patients having conjunctival bleb with less than 3mm diameter and Group 3 included patients having conjunctival bleb with more than 3mm diameter. IOP measurements were performed before the injection, 5 min after the injection and 1 hr after the injection using pneumotonometer. Statistical analysis of data was performed using independent samples t test and Mann-Whitney U test.
Thirty-one patients received ranibizumab and 33 patients received aflibercept injection. For the ranibizumab injected patients 11 eyes (35.48%) were in Group 1, 9 eyes (29.03%) were in Group 2 and 11 eyes (35.48%) were in Group 3. For the aflibercept injected patients 3 eyes (9.09%) were in Group 1, 5 eyes (15.15%) were in Group 2 and 25 eyes (75.76%) were in Group 3. Vitreous reflux was significantly differed between aflibercept and ranibizumab injected patients (p=0.001) IOP of the ranibizumab and aflibercept injection groups measured before the injection were not significantly different (p=0.261). But IOP of the groups measured 5 min after the injection and 1 hr after the injection were significantly different (p=0.009 and p= 0.128, respectively). The mean IOP of the ranibizumab and aflibercept injection groups measured 5 min after the injection were 39.16±15.99 and 28.71±14.91 mmHg, respectively. The mean IOP of the groups measured 1 hr after the injection were 17.17±6.06, and 15.00±5.07 mmHg, respectively.
Intravitreal injection of aflibercept and ranibizumab increased short-term IOP. However, IOP increase was lower in aflibercept injected patients due to more frequent vitreous reflux than ranibizumab injected patients.